Health Solutions
My video

Additional Info

  • Item Shortcode:


Osteoarthritis (OA) is a degenerative joint disease that frequently affects the hands and weight bearing joints of the body.

There is a wide spectrum of non-surgical treatments, starting with non-pharmacological options such as patient education and awareness, physical exercise and rehabilitation aids; pharmacological approaches that vary from prescription of acetaminophen, non-selective NSAIDs, selective COX-2 inhibitors agents and even opioid prescription. Other potential non-surgical therapeutic methods are chondroitin sulfate, glucosamine and other compounds in tablets or capsules, and intraarticular injections of visco-supplements, corticosteroids or blood-derived products.

Each injection has been shown to lower the pain in patients in some form, though hyaluronic acid treatments seem to be the safest and last the longest.

Carthyal® is is a line of products for OA. It includes:

  • Carthyal® Daily Care (serve the objective of delaying the natural progression of the OA. It does not serve as a definitive treatment but rather as a way to decelerate the development of the OA for patients with light to moderate symptoms. Carthyal® Daily Care can be used in concomitance but does not replace other treatments, such as the injectables. The product unique composition is a mix of actives: 600 mg of glucosamine sulfate + 600 mg of chondroitin sulfate + 350 mg of MSM (Methylsulfonylmethane) + 100 mg Boswellia + 80 mg vitamin C, in 2 capsules/day).
  • Carthyal® Injectables with hyaluronic acid (HA) replace the synovial fluid in the joint and it is indicated in the prevention and treatments of trauma-caused and degenerative diseases in synovial joints.

The intra-articular administration of Carthyal® allows:

• Immediate action by REDUCING the pain and inflammation

• Highly effective RESTORATION of the viscoelastic properties of the joints’ synovial fluid

IMPROVEMENT of the articular mobility, with functional recovery of the joint

PREVENTION the natural degradation of the joints

SAFE, WIDELY documented treatment with less side effect

CARTHYAL® Injetables is available in 3 different concentrations, different molecular weights and treatment options:

Carthyal® ONE 2,5% (75mg/3ml):

  • Cross-linked intercalated with linear hyaluronic acid, with a combined molecular weight of 3.000.000 Da (crossed linked HA fraction) + 500.000 Da (linear HA faction)
  • Treatement with 1 injection

Carthyal® PLUS 1,6% + 5% MSM (32mg/2ml HA + 100mg/2ml Methylsulfonylmethane):

  • Sodium Hyaluronate with a molecular weight of 1.800.000 Da
  • Treatement with an average of 3 injections

Carthyal® 2% (40mg/2ml):

  • Sodium Hyaluronate with a molecular weight between 800.000 and 1.200.000 Da
  • Treatement with an average of 3 injections

Carthyal® Injectables are European Medical Devices class III, produced in the E.U. under ISO 13485. Carthyal® Daily Care is a European Food Supplement, produced in a cGMP facility.

© 2017 Neosanté - Health Solutions

Privacy PolicyCookies Policy
Designed by MM Design